Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma

被引:67
作者
Dai, Liping [1 ]
Ren, Pengfei [1 ]
Liu, Mei [1 ]
Imai, Haruhiko [2 ]
Tan, Eng M. [2 ]
Zhang, Jian-Ying [1 ]
机构
[1] Univ Texas El Paso, Dept Biol Sci, El Paso, TX 79968 USA
[2] Scripps Res Inst, La Jolla, CA 92037 USA
基金
美国国家卫生研究院;
关键词
Autoantibodies; Tumor-associated antigens (TAAs); Cancer immunodiagnosis; Hepatocellular carcinoma; RNA-BINDING PROTEINS; HUMAN MALIGNANCIES; ANTIBODY DETECTION; ALPHA-FETOPROTEIN; PROSTATE-CANCER; LUNG-CANCER; ANTIGENS; CELL; NUCLEOPHOSMIN; GENE;
D O I
10.1016/j.clim.2014.03.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
To explore the possibility of using a mini-array of multiple tumor-associated antigens (TAAs) as an approach to the diagnosis of hepatocellular carcinoma (HCC), 14 TAAs were selected to examine autoantibodies in sera from patients with chronic hepatitis, liver cirrhosis and HCC by immunoassays. Antibody frequency to any individual TAA in HCC varied from 6.6% to 21.1%. With the successive addition of TAAs to the panel of TAAs, there was a stepwise increase of positive antibody reactions. The sensitivity and specificity of 14 TAAs for immunodiagnosis of HCC was 69.7% and 83.0%, respectively. This TM mini-array also identified 43.8% of HCC patients who had normal alpha-fetoprotein (AFP) levels in serum. In summary, this study further supports the hypothesis that a customized TM array used for detecting anti-TM autoantibodies can constitute a promising and powerful tool for immunodiagnosis of HCC and may be especially useful in patients with normal AFP levels. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:127 / 139
页数:13
相关论文
共 76 条
[1]
14-3-3 proteins: A historic overview [J].
Aitken, Alastair .
SEMINARS IN CANCER BIOLOGY, 2006, 16 (03) :162-172
[2]
Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? [J].
Bell, Jessica L. ;
Waechter, Kristin ;
Muehleck, Britta ;
Pazaitis, Nikolaos ;
Koehn, Marcel ;
Lederer, Marcell ;
Huettelmaier, Stefan .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2013, 70 (15) :2657-2675
[3]
Ral GTPases and cancer: linchpin support of the tumorigenic platform [J].
Bodemann, Brian O. ;
White, Michael A. .
NATURE REVIEWS CANCER, 2008, 8 (02) :133-140
[4]
An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer [J].
Brichory, FM ;
Misek, DE ;
Yim, AM ;
Krause, MC ;
Giordano, TJ ;
Beer, DG ;
Hanash, SM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (17) :9824-9829
[5]
Searching for synthetic lethality in cancer [J].
Brough, Rachel ;
Frankum, Jessica R. ;
Costa-Cabral, Sara ;
Lord, Christopher J. ;
Ashworth, Alan .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2011, 21 (01) :34-41
[6]
Awakening guardian angels: drugging the p53 pathway [J].
Brown, Christopher J. ;
Lain, Sonia ;
Verma, Chandra S. ;
Fersht, Alan R. ;
Lane, David P. .
NATURE REVIEWS CANCER, 2009, 9 (12) :862-873
[7]
Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[8]
An efficient proteomics-based approach for the screening of autoantibodies [J].
Canelle, L ;
Bousquet, J ;
Pionneau, C ;
Deneux, L ;
Imam-Sghiouar, N ;
Caron, M ;
Joubert-Caron, R .
JOURNAL OF IMMUNOLOGICAL METHODS, 2005, 299 (1-2) :77-89
[9]
Canevari S, 1996, ANN ONCOL, V7, P227
[10]
Cancer immunomics using autoantibody signatures for biomarker discovery [J].
Caron, Michel ;
Choquet-Kastylevsky, Genevieve ;
Joubert-Caron, Raymonde .
MOLECULAR & CELLULAR PROTEOMICS, 2007, 6 (07) :1115-1122